IQVIA (NYSE:IQV) issued an update on its second quarter earnings guidance on Friday morning. The company provided earnings per share guidance of $1.17-1.24 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.23. The company issued revenue guidance of $2.47-2.52 billion, compared to the consensus revenue estimate of $2.48 billion.IQVIA also updated its FY18 guidance to $5.20-5.45 EPS.
Shares of IQVIA opened at $101.63 on Friday, according to Marketbeat.com. The firm has a market capitalization of $21.05 billion, a P/E ratio of 21.00, a PEG ratio of 1.70 and a beta of 0.64. IQVIA has a one year low of $82.83 and a one year high of $110.67. The company has a current ratio of 1.16, a quick ratio of 1.16 and a debt-to-equity ratio of 1.22.
IQVIA (NYSE:IQV) last announced its earnings results on Wednesday, May 2nd. The medical research company reported $1.34 EPS for the quarter, topping the consensus estimate of $1.27 by $0.07. The firm had revenue of $2.56 billion for the quarter, compared to the consensus estimate of $2.42 billion. IQVIA had a net margin of 13.07% and a return on equity of 13.35%. The company’s revenue for the quarter was up 34.1% compared to the same quarter last year. research analysts expect that IQVIA will post 5.06 EPS for the current fiscal year.
IQV has been the topic of several recent analyst reports. SunTrust Banks reiterated a hold rating and issued a $110.00 target price on shares of IQVIA in a report on Monday, January 22nd. Mizuho set a $97.00 target price on shares of IQVIA and gave the stock a hold rating in a report on Wednesday, January 24th. JPMorgan Chase lifted their target price on shares of IQVIA from $115.00 to $120.00 and gave the stock an overweight rating in a report on Thursday, February 15th. Piper Jaffray reiterated a hold rating and issued a $103.00 target price on shares of IQVIA in a report on Thursday, February 15th. Finally, Royal Bank of Canada set a $118.00 target price on shares of IQVIA and gave the stock a buy rating in a report on Thursday, February 15th. Seven equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of Buy and an average target price of $110.47.
In other news, insider James H. Erlinger III sold 10,000 shares of the business’s stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $100.00, for a total transaction of $1,000,000.00. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Michael J. Evanisko sold 816 shares of the business’s stock in a transaction dated Monday, March 5th. The stock was sold at an average price of $100.00, for a total transaction of $81,600.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 12,527 shares of company stock worth $1,257,834. Insiders own 6.00% of the company’s stock.
IQVIA Holdings Inc provides integrated information and technology-enabled healthcare services in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Commercial Solutions, Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offers a range of cloud-based applications and related implementation, real-world insights, and reference information services; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services.
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.